• MethylGene Inc., of Montreal, appointed Rachel Humphrey executive vice president and chief medical officer.

• Micromet Inc., of Rockville, Md., appointed Joseph Lobacki senior vice president and chief commercial officer.

• Mucosis BV, of Groningen, the Netherlands, appointed Jiri Mestecky, Willem van Eden and Peter J. Openshaw to its scientific advisory board.

• Nautilus Neurosciences Inc., of Bedminster, N.J., named Peter A. Lankau executive chairman.

• NeoStem Inc., of New York, appointed Martyn D. Greenacre and Andrew L. Pecora to the board.

• NexImmune Inc., of Gaithersburg, Md., appointed Kenneth Carter CEO and named Jonathan Schneck chairman of the clinical and scientific advisory board.

• Oncolytics Biotech Inc., of Calgary, Alberta, appointed Gerard Kennealey senior vice president of clinical development and chief medical officer. George M. Gill will return to his previous role of senior vice president of regulatory affairs and also has been appointed chief safety officer.

• OncoSec Medical Inc., of San Diego, named Richard Heller, Iacob Mathiesen and Christian H. Ottensmeier to its scientific advisory board.

• Par Pharmaceutical Cos. Inc., of Woodcliff Lake, N.J., promoted Thomas J. Haughey to president and Paul V. Campanelli to chief operating officer.

• Pathwork Diagnostics Inc., of Redwood City, Calif., named Sharon Tetlow chief financial officer.

• Pernix Therapeutics Holdings Inc., of The Woodlands, Texas, appointed David Becker chief financial officer, Charles "Chuck" Hrushka vice president of sales and marketing and Leslie White director of regulatory affairs and quality assurance.